AM Mind Power Solutions, April 2012, Pages: 61
devices in India, market segmentation by Type 1 and Type 2 diabetic patients, Insulin and oral anti-diabeticdrug market in India. The report also entails the size of diabetes testing devices and insulin
Netscribes (India) Pvt. Ltd., Aug 2011, Pages: 39
pool in the world after China, the Indian market is characterized by a huge demand for anti-diabeticdrugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge
Transparency Market Research, Nov 2011, Pages: 122
, lancets, continuous blood glucose meters, syringes, insulin pumps, insulin and other insulin delivery devices and anti-diabeticdrugs. However, insulin, test strips and anti-diabeticdrugs are the most
IMARC Group, Sep 2010, Pages: 89
Insulin and Non-Insulin Anti-diabetics, The Chinese diabetes market is expected to exceed US$ 2.8 Billion by 2015.
- In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four
Netscribes (India) Pvt. Ltd., March 2012, Pages: 76
pool in the world after China, the Indian market is characterized by a huge demand for anti-diabeticdrugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge
Business Insights, May 2011, Pages: 132
their marketers are confronting competitive challenges.
- Benchmark the leading anti-diabetic pipeline products under development and evaluate the evolution of the market in the forecast period.
- Identify
Global Industry Analysts, Inc., Sep 2011, Pages: 363
Overview 6
Overview of Drug Classes in Anti-DiabeticDrugs Category 7
Rationale for Use of DPP-4 Inhibitors 7
JZMed Inc., Feb 2010, Pages: 210
their API products)
Table 5. List of Chinese API suppliers focusing on cardiovascular medicines (including their API products)
Table 6. List of Chinese API suppliers focusing on anti-diabetesdrugs (including
Aruvian's R'search, Feb 2012, Pages: 205
the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.
Anti-diabetic products include glucose
Renub Research, Feb 2009, Pages: 82
for Insulin Market (in Billion US$), 2008 – 2010
Figure 4 8: China - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 9: China – Anti-diabeticDrug Market (in Million Yuan), 2006 – 2007
Figure 4
China Market Report, Aug 2008, Pages: 50
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008 According to IMS statistics, in 2007 the scale of global anti-diabetesdrug market was $24.1 billion, up 13.7 per cent
Research In China, Feb 2011, Pages: 80
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 In 2009, the consumption of oral hypoglyceimic agents (OHAs) in China increased by 15.1% to RMB9.81 billion, accounting for approximately
Research In China, Feb 2011, Pages: 80
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 In 2009, the consumption of oral hypoglyceimic agents (OHAs) in China increased by 15.1% to RMB9.81 billion, accounting for approximately
Decision Resources, Inc., Nov 2006, Pages: 26
Statins as a Percentage of US Prices in the United States, China, Europe, and Japan
2 Average Ex-Manufacturer Prices of Three Leading Oral Anti-Diabetics as a Percentage of US Prices in the United States
Global Industry Analysts, Inc., July 2009, Pages: 1810
in Antiepileptics II-31
Calcium Channel Blockers II-31
Antidiabetics II-31
Table 14: Leading Anti-diabeticDrug Sales Worldwide: Value
Sales for Years 2005 through 2008 in US$ Billion for Actos,
Lantus, Avandia
Espicom Business Intelligence Ltd, July 2008, Pages: 204
a markedly different profile to, for example, the US or western Europe, in terms of the type of biopharmaceuticals consumed. Whereas erythropoietins, oncologics, anti-diabetics and auto-immune agents
ICON Group International, Jan 2011, Pages: 353
diseases, for human use
#7;
#7;3254121111
#7;Cancer therapy products
#7;
#7;3254121112
#7;Insulin/anti-diabetes products
#7;
#7;3254121113
#7;Other neoplasms, endocrine system, and metabolic diseases, including hormones
ICON Group International, Jan 2011, Pages: 350
preparations, affecting neoplams, the endocrine system, and metabolic diseases, for human use
#7;
#7;3254121111
#7;Cancer therapy products
#7;
#7;3254121112
#7;Insulin/anti-diabetes products
#7;
#7;3254121113
#7;Other neoplasms
